(HSIC) Henry Schein - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8064071025

Dental, Medical, Pharmaceuticals, Equipment, Software

HSIC EPS (Earnings per Share)

EPS (Earnings per Share) of HSIC over the last years for every Quarter: "2020-03": 0.91, "2020-06": -0.08, "2020-09": 0.99, "2020-12": 1, "2021-03": 1.16, "2021-06": 1.1, "2021-09": 1.15, "2021-12": 1.05, "2022-03": 1.3, "2022-06": 1.15, "2022-09": 1.09, "2022-12": 0.35, "2023-03": 0.91, "2023-06": 1.06, "2023-09": 1.04, "2023-12": 0.14, "2024-03": 0.72, "2024-06": 0.81, "2024-09": 0.78, "2024-12": 0.74, "2025-03": 0.88,

HSIC Revenue

Revenue of HSIC over the last years for every Quarter: 2020-03: 2428.871, 2020-06: 1684.399, 2020-09: 2840.146, 2020-12: 3165.725, 2021-03: 2924.961, 2021-06: 2967.223, 2021-09: 3178.315, 2021-12: 3330.522, 2022-03: 3179, 2022-06: 3030, 2022-09: 3067, 2022-12: 3371, 2023-03: 3060, 2023-06: 3100, 2023-09: 3162, 2023-12: 3017, 2024-03: 3172, 2024-06: 3136, 2024-09: 3174, 2024-12: 3191, 2025-03: 3168,

Description: HSIC Henry Schein

Henry Schein Inc is a global healthcare distributor and provider of value-added services to dental and medical practitioners. The companys diversified portfolio includes dental and medical equipment, consumables, and pharmaceuticals, as well as financial services, software solutions, and practice management tools. With a presence in multiple markets worldwide, HSIC serves a broad customer base, including dental and medical practices, laboratories, and institutional healthcare providers.

From a business perspective, HSICs strength lies in its ability to provide a one-stop-shop for healthcare professionals, offering a wide range of products and services that cater to their diverse needs. The companys global distribution network and logistics capabilities enable it to efficiently supply products to customers, while its value-added services, such as practice management software and financial services, help providers streamline their operations and improve patient care.

Analyzing the , we observe that HSICs stock price has been trending around its 20-day and 200-day simple moving averages (SMA20 and SMA200), indicating a relatively stable price action. However, the stock is currently below its 52-week high, suggesting potential for growth. The Average True Range (ATR) indicates moderate volatility, which could be an opportunity for traders. Considering the , HSICs market capitalization and price-to-earnings ratio are within a reasonable range for its industry. The forward P/E ratio suggests expected earnings growth, and the return on equity (RoE) indicates a decent level of profitability.

Based on the and , our forecast is that HSICs stock price will experience a moderate increase in the coming months, driven by the companys stable business model, diversified product portfolio, and expected earnings growth. We anticipate the stock to reach $75-$80 in the next quarter, representing a 6-10% upside from current levels. However, this forecast is contingent on the companys ability to maintain its operational momentum and navigate any potential market challenges.

Additional Sources for HSIC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

HSIC Stock Overview

Market Cap in USD 9,132m
Sector Healthcare
Industry Medical Distribution
GiC Sub-Industry Health Care Distributors
IPO / Inception 1995-11-03

HSIC Stock Ratings

Growth Rating 10.9
Fundamental 19.2
Dividend Rating 0.0
Rel. Strength 19.1
Analysts 3.5 of 5
Fair Price Momentum 68.62 USD
Fair Price DCF 86.82 USD

HSIC Dividends

Currently no dividends paid

HSIC Growth Ratios

Growth Correlation 3m 82.2%
Growth Correlation 12m 12.3%
Growth Correlation 5y -0.5%
CAGR 5y 4.59%
CAGR/Max DD 5y 0.14
Sharpe Ratio 12m 0.28
Alpha 5.85
Beta 0.341
Volatility 23.03%
Current Volume 1459.1k
Average Volume 20d 1463.2k
What is the price of HSIC shares?
As of July 03, 2025, the stock is trading at USD 74.48 with a total of 1,459,097 shares traded.
Over the past week, the price has changed by +2.32%, over one month by +7.07%, over three months by +7.55% and over the past year by +13.54%.
Is Henry Schein a good stock to buy?
Neither. Based on ValueRay´s Fundamental Analyses, Henry Schein is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 19.17 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HSIC is around 68.62 USD . This means that HSIC is currently overvalued and has a potential downside of -7.87%.
Is HSIC a buy, sell or hold?
Henry Schein has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold HSIC.
  • Strong Buy: 3
  • Buy: 4
  • Hold: 8
  • Sell: 0
  • Strong Sell: 1
What are the forecasts for HSIC share price target?
According to our own proprietary Forecast Model, HSIC Henry Schein will be worth about 74.7 in July 2026. The stock is currently trading at 74.48. This means that the stock has a potential upside of +0.31%.
Issuer Target Up/Down from current
Wallstreet Target Price 76.4 2.5%
Analysts Target Price 76.4 2.5%
ValueRay Target Price 74.7 0.3%